A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Health Adult Subjects
In brief
he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups
Key facts
- Study ID
- NCT07199270
- Run by
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- People needed
- 64
- Starts
- 2025-09-18
- Expected to finish
- 2026-12-16
- Last updated by the study team
- 2025-09-30
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy adult subjects
- Signed informed consent
You may not qualify if…
- History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
- Prior use of drug targeting TNF-like cytokine 1A
- history of malignant tumor
- psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)
Where it is running
- Beijing Friendship hospital, Capital Medical University — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.